@socalurologyinstitute's TRT and HCG claims, fact-checked

What did @socalurologyinstitute actually say?

A urologist from SoCal Urology Institute made a fairly specific claim: HCG can be used as a standalone treatment to raise testosterone, and it does this without causing testicular atrophy, infertility, or the other side effects typically associated with standard TRT. They called it "a great option, especially for younger guys who aren't ready to shut off your body's production of testosterone." The framing was enthusiastic, two-thumbs-up enthusiastic, and the advice was pointed: skip the peptides, skip the online orders, and go with HCG monotherapy instead.

This is not fringe advice. HCG monotherapy is a recognized clinical approach, and the urologist is not pulling this from nowhere. But "absolutely yes" and "two thumbs up" deserve some scrutiny before anyone runs to their doctor asking for a protocol.

Does the science back this up?

Mostly, yes. HCG stimulates Leydig cells in the testes to produce testosterone by mimicking luteinizing hormone (LH). That mechanism is well-established and not seriously contested. What is more complicated is how reliably it works as a monotherapy, and whether the side effect profile is as clean as presented.

A 2013 study by Depenbusch et al. in the European Journal of Endocrinology confirmed that HCG can maintain intratesticular testosterone and spermatogenesis in men with secondary hypogonadism. A 2002 study by Coviello et al. in the Journal of Clinical Endocrinology and Metabolism showed that intratesticular testosterone concentrations are preserved with HCG use even when exogenous testosterone is suppressing LH. More directly relevant, a 2005 paper by Roth et al. in the Journal of Urology showed that HCG monotherapy in adolescent males with hypogonadotropic hypogonadism produced meaningful testosterone increases.

So the mechanism works. The clinical outcomes in secondary hypogonadism are reasonably supported. The concern is that HCG monotherapy has limitations in primary hypogonadism, where the testes themselves are the problem, and those limitations went unmentioned.

What did they get wrong (or right)?

They got the core biology right. HCG does stimulate endogenous testosterone production. It does preserve testicular size and function, and it does avoid the suppression of the hypothalamic-pituitary-gonadal axis that exogenous testosterone causes. For younger men with secondary hypogonadism who want to preserve fertility, this is a genuinely reasonable clinical path.

What they got wrong, or at least incomplete: the claim that HCG "doesn't cause any other side effects associated with TRT" is an overstatement. HCG can elevate estradiol, sometimes significantly, because aromatase activity in Leydig cells converts testosterone to estrogen. This can cause gynecomastia, mood changes, and water retention in some patients. A 2019 review by Ramasamy et al. in the Journal of Urology specifically flagged elevated estradiol as a clinically relevant concern with HCG use.

The urologist also did not specify that HCG monotherapy is most appropriate for secondary hypogonadism, not primary. Telling every young guy to "get HCG" without that distinction could lead someone with primary hypogonadism, where Leydig cells are damaged or absent, to pursue a treatment that simply will not work for them.

What should you actually know?

HCG monotherapy is a legitimate, well-studied option for specific patients. It is not a universal substitute for TRT, and the side-effect-free framing overpromises. Before anyone pursues this route, a few things matter: your diagnosis has to be secondary hypogonadism, confirmed by labs showing low LH or FSH alongside low testosterone. If your LH is already elevated and your testosterone is low, your testes are the problem, and HCG will not fix that.

Second, estradiol monitoring is not optional. The aromatase activity in Leydig cells means some men on HCG will see estradiol climb, and that carries real symptoms. This is manageable, but it needs to be tracked.

Third, HCG availability has changed. In 2020, the FDA removed HCG from its list of drugs eligible for compounding, which significantly affected access through telehealth and compounding pharmacies. Some providers now use choriogonadotropin alfa (Pregnyl, Novarel) as the branded alternative. Access, cost, and regulatory status vary and should be confirmed with a licensed provider.

The urologist's advice to avoid unregulated online peptide purchases is correct and worth repeating. Sourcing hormones outside a licensed medical relationship is not a gray area, it is a documented patient safety risk.